What happened
According to a filing with the U.S. Securities and Exchange Commission published on Oct. 09, 2025, BDF-GESTION sold 4,149 shares of Eli Lilly (LLY +0.12%) stock during the quarter. The estimated transaction value was $3.09 million, using the average unadjusted closing price for the quarter. After the trade, the fund held 19,949 shares, worth $15.22 million at quarter end.
What else to know
BDF-GESTION reduced its stake in Eli Lilly and Company; the holding now accounts for 1.8% of the fund’s 13F AUM, down from 2.1% in the previous quarter
Top holdings after the filing:
NVDA: $89.5 million (10.7% of AUM) as of September 30, 2025
MSFT: $78.5 million (9.4% of AUM) as of September 30, 2025
AAPL: $75.5 million (9.0% of AUM) as of September 30, 2025
AVGO: $37.8 million (4.5% of AUM) as of September 30, 2025
META: $35.9 million (4.3% of AUM) as of September 30, 2025
As of October 8, 2025, shares were priced at $845.72, down 7.44% year-to-date through October 8, 2025 and underperformed the S&P 500 by 23.7 percentage points over the past year
Company Overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $53.26 billion |
| Net Income (TTM) | $13.80 billion |
| Dividend Yield | 0.68% |
| Price (as of market close 10/08/25) | $845.72 |
Company Snapshot
Eli Lilly and Company offers a broad portfolio of pharmaceuticals for diabetes, oncology, immunology, neuroscience, and other therapeutic areas; including Mounjaro, Zepbound, Taltz, and Verzenio.
Generates revenue primarily through the discovery, development, manufacturing, and global sale of branded prescription medicines, leveraging a robust pipeline and strategic collaborations.
With a focus on patients requiring innovative therapies for chronic and acute conditions.
Eli Lilly and Company is a global pharmaceutical leader with a diversified product lineup and a strong focus on research-driven innovation. The company's scale and established presence in key therapeutic categories support consistent revenue generation and competitive positioning. Strategic partnerships and a commitment to advancing new treatments underpin its long-term growth strategy.
Foolish take
BDF-Gestion's bet on Eli Lilly wasn't the biggest one it made in the third quarter, but it was significant. Valued at $15.2 million, it was the firm's eighth-largest holding at the end of September.
Lilly's dual GLP-1/GIP receptor agonist, tirzepatide, could become the top-selling drug of all time. First approved as Mounjaro for diabetes in 2022, and again as Zepbound for obesity in 2023, it's already a mega-blockbuster.
In the first half of 2025, combined sales of Zepbound and Mounjaro soared 121% to reach $14.7 billion. It's just one of dozens of treatments that Lilly markets, but it's already responsible for a majority of total revenue. Sales could soar even further. Estimates on Wall Street vary, but some analysts expect combined sales of tirzepatide and similar drugs to reach a whopping $100 billion annually by 2030.
Tirzepatide is an important revenue stream, but it isn’t the only growth driver in Eli Lilly’s product lineup. Sales of Ebglyss, a treatment for eczema, could soar going forward. Long-term trial data recently showed that it helped about 80% of patients achieve clearance on at least 75% of their bodies.
Glossary
13F reportable assets: Assets that institutional investment managers must disclose quarterly to the SEC, showing holdings in certain securities.
Assets under management (AUM): The total market value of investments managed by a fund or investment firm on behalf of clients.
Stake: The ownership interest or number of shares held in a company by an investor or fund.
Quarter: A three-month period used by companies and investors for financial reporting and performance measurement.
Filing: An official document submitted to a regulatory authority, often detailing financial or ownership information.
Top holdings: The largest investments in a fund's portfolio, typically ranked by market value.
Dividend yield: The annual dividend payment divided by the stock's price, expressed as a percentage.
Therapeutic areas: Categories of diseases or medical conditions targeted by a company's pharmaceutical products.
Pipeline: The set of drug candidates a pharmaceutical company is developing, from early research to late-stage trials.
Strategic collaborations: Partnerships between companies to jointly develop, market, or distribute products or technologies.
TTM: The 12-month period ending with the most recent quarterly report.
